Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management

Roccatello, Dario; Sciascia, Savino; Rossi, Daniela; Fenoglio, Roberta

doi:10.1007/s40265-022-01824-x

Cited by 5 publications

(11 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Refractory Lupus Nephritis is de ned as an inadequate response to SOC therapy (10). This condition is associated with poor outcome, including end stage renal disease (4).…”

Section: Discussionmentioning

confidence: 99%

“…Refractory LN is commonly de ned as either no response to standard SOC, i.e., failure to improve within 3-4 months, or not achieving partial response after 6-12 months, or complete response to SOC after 2 years of treatment (10). A more comprehensive de nition should include the double attempt with both MMF and CYC-based regimen (10). However, concerns arise on the possible adverse effects of a prolonged ineffective immunosuppression, even though LN must require a relatively long time to achieve response, especially in the patients with nephrotic-range proteinuria at baseline who often need up to 12 more months to achieve complete clinical response).…”

Section: Introductionmentioning

confidence: 99%

“…While the issue of refractory SLE has been especially addressed for renal involvement, the de nition of refractory LN is in itself a matter of debate since the standard parameters of response, i.e., proteinuria and renal function, do not clearly discriminate between activity and irreversible damage (9). Refractory LN is commonly de ned as either no response to standard SOC, i.e., failure to improve within 3-4 months, or not achieving partial response after 6-12 months, or complete response to SOC after 2 years of treatment (10). A more comprehensive de nition should include the double attempt with both MMF and CYC-based regimen (10).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Daratumumab monotherapy for refractory lupus nephritis

Roccatello¹,

Fenoglio²,

Caniggia³

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Refractory lupus nephritis (RLN) is a clinical condition with high risk of a poor outcome and often life-threatening. Six patients (one male and 5 females), aged 41.3 years (range 20 to 61 years) were treated with Daratumumab monotherapy, a monoclonal antibody targeting CD38 which is highly expressed on the surface of many immune cells, especially plasma cells. The treatment protocol consisted of 16 mg/kg daratumumab administered intravenously weekly for 8 weeks, then every two weeks 8 more times, and lastly monthly (maximum 8 infusions). All patients failed previous treatments with the Standard of Care (SOC) including mycophenolate mofetil (MMF), cyclophosphamide (CYC), azathioprine and rescue therapies including Rituximab (RTX), Ocrelizumab, Belimumab, and iv IgG. One out of six patients did not show clinical response after 6 months of therapy, and Daratumumab was discontinued. Five patients showing a clinical response over the same period continued to be treated and reached a 12-month observation. Renal biopsy performed before daratumumab administration revealed a class IV LN in 1 patient, class V LN in 1 patient, class III + V LN in 1 patient and class IV + V LN in the other 2. Three patients achieved a complete renal response and the other two a partial renal response. A significant decrease in proteinuria from 5.6 gr/24 hours to 0.8 g/24 hours (p = 0.001) was achieved at 12 months. The mean value of serum Creatinine (sCr) decreased from 2.3 to 1.5 mg/dl. Improvement of clinical symptoms was paralleled by seroconversion of anti-double-stranded DNA antibodies (p = 0.03), significant decrease in interferon-gamma values (p = 0.0006), BMCA-B-cell maturation antigen (p = 0.0005) and soluble CD163 levels (p = 0.045), and increase in C4 (p = 0.018) and IL 10 levels (p = 0.0006). Clinical remission was substantiated by improvement of SLEDAI-2K score (p = 0.03). Daratumumab was generally well tolerated. These data suggest that Daratumumab administered alone (i.e., without any other immunosuppressant or agents targeting B-cell activating factor) is highly effective in RLN.

show abstract

“…Refractory Lupus Nephritis is de ned as an inadequate response to SOC therapy (10). This condition is associated with poor outcome, including end stage renal disease (4).…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Daratumumab monotherapy for refractory lupus nephritis

Roccatello¹,

Fenoglio²,

Caniggia³

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Refractory LN is commonly defined as either no response to SOC—that is, failure to improve within 3–4 months or not achieving partial response after 6–12 months—or complete response to SOC after 2 years of treatment 2 . A more comprehensive definition should include the double attempt with both MMF-based and CYC-based regimens 2 .…”

Section: Mainmentioning

confidence: 99%

Daratumumab monotherapy for refractory lupus nephritis

Roccatello

Fenoglio

Caniggia

et al. 2023

Nat Med

Self Cite

View full text Add to dashboard Cite

Treatment-refractory lupus nephritis (LN) has a high risk of a poor outcome and is often life-threatening. Here we report a case series of six patients (one male and five females) with a median age of 41.3 years (range, 20–61 years) with refractory LN who received renal biopsies and were subsequently treated with intravenous daratumumab, an anti-CD38 monoclonal antibody (weekly for 8 weeks, followed by eight biweekly infusions and up to eight monthly infusions). One patient did not show any improvement after 6 months of therapy, and daratumumab was discontinued. In five patients, the mean disease activity, as assessed by the Systemic Lupus Erythematosus Disease Activity 2000 index, decreased from 10.8 before treatment to 3.6 at 12 months after treatment. Mean proteinuria (5.6 g per 24 h to 0.8 g per 24 h) and mean serum creatinine (2.3 mg dl−1 to 1.5 mg dl−1) also decreased after 12 months. Improvement of clinical symptoms was accompanied by seroconversion of anti-double-stranded DNA antibodies; decreases in median interferon-gamma levels, B cell maturation antigen and soluble CD163 levels; and increases in C4 and interleukin-10 levels. These data suggest that daratumumab monotherapy warrants further exploration as a potential treatment for refractory LN.

show abstract

“…The TULIP trial and the BLISS‐LN trials achieved success in SLE during recent years and brought SLE into the biological era with anifrolumab and belimumab 2,3 . However, there are still obstacles in treatment, such as refractory neuropsychiatric SLE and lupus nephritis 4 …”

Section: Introductionmentioning

confidence: 99%

From concept to reality: CAR‐T therapy as a glimmer of hope for systemic lupus erythematosus patients

Lin,

Lee,

Shih

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management

Cited by 5 publications

References 108 publications

Daratumumab monotherapy for refractory lupus nephritis

Daratumumab monotherapy for refractory lupus nephritis

Daratumumab monotherapy for refractory lupus nephritis

From concept to reality: CAR‐T therapy as a glimmer of hope for systemic lupus erythematosus patients

Contact Info

Product

Resources

About